

Applicants: David Bebbington, et al.
Application No.: 10/775,699

REMARKS

The Claim Amendments

Applicants have amended claims 1, 12, and 13 so that R^y and R⁸ are taken together to form a fused, optionally substituted benzo ring. Support for this amendment may be found in the specification as originally filed (see e.g. page 48, line 25).

Applicants have amended claims 12 and 13 to remove the word "and" and to add a period at the end of the claim.

Applicants have amended claim 8 to delete the repeated letter "a" in the definition of Ring D.

None of these amendments adds new matter.

The Response

35 U.S.C. §112, First Paragraph

The Examiner has rejected claims 1, 12, 13, 15, and 16 under 35 U.S.C. 112, first paragraph because the specification, "while being enabling for making and using the compound of formula II wherein R^y does not form a ring (i.e., pyrimidyl core), or R^y and R⁸ form a benzon ring (i.e., quinazolinyl core), does not reasonably provide enablement for making and using of the compound of formula II wherein R^y and R⁸ form other heterocyclic fused rings." Applicants have amended claims 1, 12 and 13 so that R^y and R⁸ are taken together to form a fused, optionally substituted benzo ring. Accordingly, applicants respectfully request that the Examiner withdraw the §112, first paragraph rejection.

Claim Objections

The Examiner contends that claims 8-11 and 14 are indefinite "as being dependent upon a rejected base claim." Applicants have amended claim 1 to overcome the Examiner's claim 1 rejections, thus obviating the objection.


Applicants: David Bebbington, et al.
Application No.: 10/775,699

CONCLUSION

Applicants request that the Examiner enter the above amendments, consider the foregoing remarks, and allow the pending claims to issue.

If the Examiner believes that a telephone discussion would further issuance of this application, the Examiner is invited to call the attorney or agent at any time.

Respectfully submitted,



Jennifer G. Che (Reg. No. 58,035)
Agent for Applicants
Lisa A. Dixon (Reg. No. 40,995)
Attorney for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6525
Fax: (617) 444-6483